



## Intercept to Present at Upcoming Investor Conferences in September

August 23, 2019

NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating at the following upcoming investor conferences:

- **Baird 2019 Global Healthcare Conference** in New York, NY at 3:10 p.m. ET on Wednesday, September 4, 2019
- **Citi 14<sup>th</sup> Annual Biotech Conference** in Boston, MA at 12:45 p.m. ET on Thursday, September 5, 2019

Webcast information for these events will be available on the investor page of Intercept's website at <http://ir.interceptpharma.com>. Archived webcasts will be available on Intercept's website for approximately two weeks.

### ***About Intercept***

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit [www.interceptpharma.com](http://www.interceptpharma.com) or connect with the company on [Twitter](#) and [LinkedIn](#).

### CONTACT

For more information about Intercept, please contact:

Justine O'Malley

+1-646-931-1180

[investors@interceptpharma.com](mailto:investors@interceptpharma.com)

Media inquiries: [media@interceptpharma.com](mailto:media@interceptpharma.com)



Source: Intercept Pharmaceuticals, Inc.